Blog Archive
-
▼
2007
(90)
-
▼
October
(27)
- Wyeth, Tygacil for the Treatment of Patients with ...
- Tomophase, First Cross-Sectional Images Of Human B...
- Poniard Pharmaceuticals, Orphan Medicinal Product...
- Pharmion , Phase 3 Study of Amrubicin in Small Cel...
- DEY, Clinical Trials for Perforomist™ Inhalation S...
- Altair Therapeutics Will Develop Antisense Drugs f...
- Telik, TELCYTA Clinical Development
- Abraxis Bioscience, Special Protocol Assessment fo...
- Critical Therapeutics, Phase III Trial of Zileuton...
- Cellestis, FDA Approval for Blood Test for Detecti...
- Threshold Pharmaceuticals would stop enrollment in...
- Oridion, New Smart Capnography System for Improved...
- Proteolix , Carfilzomib in Subjects with Relapsed ...
- Nektar Therapeutics, NKTR-102 (PEG-Irinotecan) in ...
- Broncus Technologies, Encouraging Results Reported...
- Exelixis, Phase II study of XL647 in Patients with...
- MediciNova Positive Phase IIa Clinical Study Resul...
- PTC Therapeutics, Phase 2 Results of PTC124 in Cys...
- Inspire, Phase 3 Cystic Fibrosis Trial
- MedImmune , Phase 2 Safety Data for Anti-RSV Antib...
- Gilead, Phase III Study of Aztreonam Lysine for In...
- Invacare , new Invacare® XPO2™ extremely portable ...
- development of NOV-002, Novelos' lead compound in ...
- Critical Therapeutics, Phase I Clinical Trial of t...
- Emphasys Medical, PMA Submission for Bronchial Val...
- Discovery Laboratories, Surfaxin Process Validatio...
- FASgen, Significant Milestone in Its Cancer Drug D...
-
▼
October
(27)
Oct 17, 2007
DEY, Clinical Trials for Perforomist™ Inhalation Solution to be Presented at CHEST 2007
October 16, 2007 - Dey, L.P. , a subsidiary of Mylan Inc. (NYSE: MYL), announces three clinical data presentations will be given at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians (ACCP) on Wednesday, October 24, 2007 at the McCormick Place Convention Center in Chicago. Data will be presented from two safety studies that were included as part of the New Drug Application (NDA) filing to the U.S. Food and Drug Administration (FDA) for Perforomist™ Inhalation Solution. The third presents results from a Phase IIIb study of the concomitant use of Perforomist™ Inhalation Solution with tiotropium for the treatment of COPD... Dey's Press Release-
Libellés :
Chronic Obstructive Pulmonary Disease (COPD),
Dey